People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotech, Biotechnology, Software / Tech, AI / ML, Other Technology, Media & Content
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nautilus Biotechnology, Inc. | — | Biotech | Series D+ | $303.3M | $6.0B | 2020 |
| Variant Bio, Inc. | — | Biotechnology | Series D+ | $127.7M | $2.8B | 2021 |
| Avalanche Technology Inc | — | Software / Tech | Series B | $98.0M | $281.3M | 2016 |
| Super.AI Inc. | — | AI / ML | Series A | $30.1M | $87.4M | 2024 |
| Voodle, Inc. | — | Other Technology | Series A | $27.5M | $13.1M | 2017 |
| Niche Interactive Media Inc. | — | Media & Content | Series A | $24.1M | $64.6M | 2022 |
| J2 Software Solutions,Inc. | — | Software / Tech | Series A | $21.1M | $151.1M | 2022 |
| Unearth Technologies Inc. | — | Software / Tech | Series A | $14.2M | $52.1M | 2019 |
| Polyarc, Inc. | — | Other Technology | Series A | $11.9M | $19.0M | 2025 |
Stuart Nagae at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stuart Nagae on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sivaramakichenane Somasegar | 2 | 3 |
| Michael Galgon | 1 | 14 |
| Gaurav Garg | 1 | 12 |
| Adam Goulburn | 1 | 10 |
| Vic Gatto | 1 | 9 |
| Crom Carmichael | 1 | 9 |
| Vijay Pande | 1 | 9 |
| Josh Wolfe | 1 | 8 |
| Cameron Newton | 1 | 8 |
| TIMOTHY PORTER | 1 | 7 |
| Bob More | 1 | 6 |
| Robert Cooper | 1 | 5 |
| Umesh Padval | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Raymond Tonsing | 1 | 4 |
| MIKA SALMI | 1 | 4 |
| Elena Viboch | 1 | 4 |
| Matthew Posard | 1 | 4 |
| William Stewart | 1 | 4 |
| Eric Stang | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.